ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 8

Supercharged Sox9 Protein Induces Chondrogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells

Yuan K. Chou1, Shili Wu2, Camilo Avendano2, Tom Caldwell2, Brian Maniaci2, Kentaro Yomogida1, Yong Zhu2 and Cong-Qiu Chu3, 1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 2VivoScript, Inc, Costa Mesa, CA, 3Rheumatology, Oregon Health & Science Univ and Portland VA Medical Center, Portland, OR

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: chondrocytes, mesenchymal stem cells and transcription factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoarthritis (OA) is characterized by progressive breakdown of articular cartilage. Regeneration of cartilage has been an attractive approach to OA therapy. Sox9 is a transcription factor belonging to the Sox (Sry-type HMG box) gene family and has been identified as a “master regulator” of the chondrocyte phenotype. We investigated whether a super positively charged cell penetrating Sox9 fusion protein can induce bone marrow-derived mesenchymal stem cells (MSC) to differentiate into chondrocytes for potential use to promote cartilage regeneration in situ. 

Methods: A bioactive supercharged Sox9 (scSox9) was generated by fusing Sox9 with a super positively charged green fluorescence protein (GFP) using molecular engineering technology. Human bone marrow-derived MSC at passage 5 were cultured with scSox9 in monolayer or in cell aggregate for differentiation into chondrocytes. Chondrogenesis was verified by toluidine blue staining for aggrecan and by RT-PCR and immunohistochemistry for collagen type I, II and X production.

Results: scSox9 could readily enter HHF cells, a human skin fibroblasts-derived cell line and  human bone marrow- derived MSC. After one hour incubation with scSox9, both HHF cells and MSC showed intracellular expression of green fluorescence indicating entry of scSox9 into these cells. scSox9 was able to induce MSC proliferation and differentiation with no requirement of additional growth factors. The number of scSox9 treated MSC was increased two folds after 72 hours in culture compared with scGFP treated MSC. As early as 48 hours, scSox9 treated MSC started changing morphology to chondrocyte-like cells and the changed morphology maintained for 21 days in culture when observation was ended. These morphologically changed cells stained positive for toluidine blue, which suggests aggrecan production. Furthermore, scSox9 induced collagen type II expression and down- regulated collagen type I and type X production. Most importantly, one time addition of scSox9 at the initiation of chondrogenesis was sufficient to induce MSC chondrogenic differentiation and maintain the chondrocyte phenotype.

Conclusion: These in vitro data demonstrated that scSox9 is able to enter bone marrow-derived MSC and induce chondrogenesis and maintain chondrocyte phenotype. Further investigation is warranted for the potential therapeutic use in cartilage repair by promoting regeneration of hyaline cartilage.


Disclosure:

Y. K. Chou,
None;

S. Wu,

VivoScript, Inc,

3;

C. Avendano,

VivoScript, Inc,

3;

T. Caldwell,

VivoScript, Inc,

3;

B. Maniaci,

VivoScript, Inc,

3;

K. Yomogida,
None;

Y. Zhu,

VivoScript, Inc,

3;

C. Q. Chu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/supercharged-sox9-protein-induces-chondrogenic-differentiation-of-bone-marrow-derived-mesenchymal-stem-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology